4.8 Article

Multistage and transmission-blocking targeted antimalarials discovered from the open-source MMV Pandemic Response Box

Journal

NATURE COMMUNICATIONS
Volume 12, Issue 1, Pages -

Publisher

NATURE RESEARCH
DOI: 10.1038/s41467-020-20629-8

Keywords

-

Funding

  1. Medicines for Malaria Venture [MMV18/0001]
  2. South African Medical Research Council
  3. South African Department of Science and Innovation
  4. South African Technology Innovation Agency (TIA) [MMV18/0001]
  5. DST/NRF South African Research Chairs Initiative Grant [UID: 84627, UID: 171215294399, UID: 64767]
  6. CSIR Parliamentary Grant
  7. Bill and Melinda Gates Foundation [OPP1054480, OPP 1054480]
  8. Australian NHMRC [APP1072217]

Ask authors/readers for more resources

This study screened the Medicines for Malaria Venture Pandemic Response Box against different life cycle stages of Plasmodium, identifying unique compounds with multistage or stage-specific activity, including potent transmission-blocking drugs. Mechanistic investigations revealed that ML324 inhibits histone demethylation, leading to aberrant gene expression and death in gametocytes, while parasites resistant to SQ109 implicate the V-type H+-ATPase as a druggable target.
Chemical matter is needed to target the divergent biology associated with the different life cycle stages of Plasmodium. Here, we report the parallel de novo screening of the Medicines for Malaria Venture (MMV) Pandemic Response Box against Plasmodium asexual and liver stage parasites, stage IV/V gametocytes, gametes, oocysts and as endectocides. Unique chemotypes were identified with both multistage activity or stage-specific activity, including structurally diverse gametocyte-targeted compounds with potent transmission-blocking activity, such as the JmjC inhibitor ML324 and the antitubercular clinical candidate SQ109. Mechanistic investigations prove that ML324 prevents histone demethylation, resulting in aberrant gene expression and death in gametocytes. Moreover, the selection of parasites resistant to SQ109 implicates the druggable V-type H+-ATPase for the reduced sensitivity. Our data therefore provides an expansive dataset of compounds that could be redirected for antimalarial development and also point towards proteins that can be targeted in multiple parasite life cycle stages. Here, Reader et al. screen the Medicines for Malaria Venture Pandemic Response Box in parallel against Plasmodiumasexual and liver stage parasites, stage IV/V gametocytes, gametes, oocysts and as endectocides. They identify two potent transmission-blocking drugs: a histone demethylase inhibitor ML324 and the antitubercular SQ109.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available